Hymenolepis infection medical therapy

Jump to navigation Jump to search

Hymenolepis infection Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Hymenolepis infection from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hymenolepis infection medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hymenolepis infection medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hymenolepis infection medical therapy

CDC on Hymenolepis infection medical therapy

Hymenolepis infection medical therapy in the news

Blogs on Hymenolepis infection medical therapy

Directions to Hospitals Treating Hymenolepis infection

Risk calculators and risk factors for Hymenolepis infection medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

A prescription drug called praziquantel is given. The medication causes the tapeworm to dissolve within the intestines. Praziquantel is generally well tolerated. Sometimes more than one treatment is necessary.

Medical Therapy

Pharmacotherapy

Acute Pharmacotherapies

Praziquantel as a single dose (25 mg/kg) is the current treatment of choice for hymenolepiasis and has an efficacy of 96%. Single dose albendazole (400 mg) is also very efficacious (>95%). Niclosamide has also been used.

A three-day course of nitazoxanide is 75–93% efficacious. The dose is 1g daily for adults and children over 12; 400mg daily for children aged 4 to 11 years; and 200mg daily for children aged 3 years or younger.[1][2]

References

  1. Ortiz JJ, Favennec L, Chegne NL, Gargala G. (2002). "Comparative clinical studis of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis, and hymenolepiasis in children from Peru". Trans R Soc Trop med Hyg. 96: 193&ndash, 96. PMID 12055813.
  2. Reomero-Cabello R, Guerro LR, Munez-Gracia MR, Geyne Cruz A. (1997). "Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in México". Trans R Soc Trop Med Hyg. 91: 701&ndash, 3.